Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Harrow Health Inc (HROW)
NASDAQ:HROW
HROW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.30 - $59.23
Previous CloseN/A
Volume51.77K
Average Volume (3M)328.50K
Market Cap
$1.09B
Enterprise Value$1.73B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Mar 13, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding35,614,720
10 Day Avg. Volume328,225
30 Day Avg. Volume328,504
Standard Deviation0.21
R-Squared0.03
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.41
Price to Cash Flow (P/CF)91.80
P/FCF Ratio115.10
Enterprise Value/Market Cap1.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit19.09
Enterprise Value/Ebitda1.97K
Forecast
1Y Price Target
$59.75Price Target Upside97.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Harrow Health News
PremiumCompany Announcements
Harrow Inc. Reports Strong Q3 2024 Growth
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe increase in Harrow's price target from $50 to $73 is driven by significant growth in sales estimates for core products like TRIESENCE, VEVYE, and IHEEZO.
Market ExpansionVEVYE's improving payer coverage suggests it could be a net share gainer as it heads into the end of the year.
Product PortfolioHarrow's strategic developments include the relaunch of TRIESENCE and advancements with MELT-300, which are expected to add significant revenue streams.
Bears Say
Brand AwarenessIHEEZO's steady growth yet to reflect significant headroom to expansion of brand awareness and access.
Operational CostsFinancial position is expected to strengthen due to market-above revenue growth surpassing operational expenses, yet challenges in operational efficiency could pose a risk.
Top-Line EstimatesLowered near-term top-line estimates while longer-term growth prospects remain largely unchanged.
---
Ownership Overview
13.75% Insiders
10.42% Mutual Funds
27.89% Other Institutional Investors
37.08% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HROW FAQ
What was Harrow Health Inc’s price range in the past 12 months?
Harrow Health Inc lowest stock price was $9.30 and its highest was $59.23 in the past 12 months.
What is Harrow Health Inc’s market cap?
Harrow Health Inc’s market cap is $1.09B.
When is Harrow Health Inc’s upcoming earnings report date?
Harrow Health Inc’s upcoming earnings report date is Mar 13, 2025 which is in 20 days.
How were Harrow Health Inc’s earnings last quarter?
Harrow Health Inc released its earnings results on Nov 13, 2024. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.052 by -$0.068.
Is Harrow Health Inc overvalued?
According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued.
Does Harrow Health Inc pay dividends?
Harrow Health Inc does not currently pay dividends.
What is Harrow Health Inc’s EPS estimate?
Harrow Health Inc’s EPS estimate is >-0.01.
How many shares outstanding does Harrow Health Inc have?
Harrow Health Inc has 35,614,720 shares outstanding.
What happened to Harrow Health Inc’s price movement after its last earnings report?
Harrow Health Inc reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.052. Following the earnings report the stock price went down -17.259%.
Which hedge fund is a major shareholder of Harrow Health Inc?
Currently, no hedge funds are holding shares in HROW
---
Harrow Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.75 (97.46% Upside)
$59.75 (97.46% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $711.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.9%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
186.50%
12-Months-Change
Fundamentals
Return on Equity
-50.10%
Trailing 12-Months
Asset Growth
22.76%
Trailing 12-Months
Company Description
Harrow Health Inc
Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits.
---
HROW Company Deck
---
HROW Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and strategic product launches, particularly with VEVYE and the retina pivot strategy. However, inventory issues with VEVYE and seasonal impacts on revenue were noted as challenges.Read More>---
HROW Stock 12 Month Forecast
Average Price Target
$59.75
▲(97.46% Upside)
Technical Analysis
Prophase Labs
―
EyePoint Pharmaceuticals
―
Ocular Therapeutix
―
Clearside Biomedical
―
scPharmaceuticals
―
Best Analysts Covering HROW
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+105.31%
reiterated a buy rating 3 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +105.31% per trade.
---